+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
R

Actively Recruiting

This research aims to support the creation and use of a database for patients with coronary microvascular disease CMD. The study focuses on collecting, storing, and sharing data about CMD patients to help research in this area. It is an observational study led by Medstar Health Research Institute to better understand CMD through detailed patient information. The study involves identifying patients with CMD and gathering their medical data both retrospectively and prospectively. Researchers will follow these patients for up to five years to observe short-term and long-term outcomes related to the disease. This process helps build a registry to support ongoing and future research. Participants will be part of a data registry where their medical information is collected and stored securely. Researchers will analyze this information over time to study patient outcomes. The main goal is to establish and maintain a CMD patient registry over ten years, supporting a better understanding of the disease and its effects.

Age: 18Years +All Genders
3 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
R

Actively Recruiting

Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.

Age: 18Years +All Genders
134 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
C

Actively Recruiting

Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.

Age: 18Years +All GendersPhase 3
846 locations

1-10 of 13

1